GGrantIndex
← Leaderboards

Adi Cohen

Columbia University Health Sciences

$3,447,742
Attributed
$4,076,448
Total exposure
4
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $884K · FY200721
$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21

Funding mix

By agency

FDA$3,190,518 · 2
NIH$885,930 · 2

By mechanism

R01$3,190,518 · 2
K23$641,930 · 1
R03$244,000 · 1

Top collaborators

Most similar at Columbia University Health Sciences

Same institution · by research overlap

Others in their field

Top investigators on “Pharmaceutical Preparations

Research focus

Pharmaceutical PreparationsOsteoporosisWomanPostmenopauseClinical PhenotypeAffectPathogenesisPremenopauseBone TurnoverBone DensityBiopsyDiagnosisCharacteristicsCeliac DiseaseClinical ManagementEtiologyElementsBone DiseasesEpidemiologyAnorexia NervosaElectronsCareerCase-Control StudiesBone

Grant awards (16)

Pregnancy and lactation associated osteoporosis: Bone microstructure and metabolism, genotypic characteristics, natural history and biomarkers of disease severity$393,866
R01 · FY2021 · FD · contact PI
Pregnancy and lactation associated osteoporosis: Bone microstructure and metabolism, genotypic characteristics, natural history and biomarkers of disease severity$387,210
R01 · FY2020 · FD · contact PI
Teriparatide for Idiopathic Osteoporosis in Premenopausal Women: A Phase 2 Study$499,998
R01 · FY2019 · FD
Pregnancy and lactation associated osteoporosis: Bone microstructure and metabolism, genotypic characteristics, natural history and biomarkers of disease severity$384,010
R01 · FY2019 · FD · contact PI
Pregnancy and lactation associated osteoporosis: Bone microstructure and metabolism, genotypic characteristics, natural history and biomarkers of disease severity$384,010
R01 · FY2018 · FD · contact PI
Teriparatide for Idiopathic Osteoporosis in Premenopausal Women: A Phase 2 Study$356,733
R01 · FY2018 · FD
Teriparatide for Idiopathic Osteoporosis in Premenopausal Women: A Phase 2 Study$400,681
R01 · FY2017 · FD
Pregnancy and lactation associated osteoporosis: Bone microstructure and metabolism, genotypic characteristics, natural history and biomarkers of disease severity$384,010
R01 · FY2017 · FD · contact PI
IGF-1, bone turnover and response to teriparatide in premenopausal women with IOP$80,000
R03 · FY2015 · AR · contact PI
IGF-1, bone turnover and response to teriparatide in premenopausal women with IOP$82,000
R03 · FY2014 · AR · contact PI
IGF-1, bone turnover and response to teriparatide in premenopausal women with IOP$82,000
R03 · FY2013 · AR · contact PI
Bone Quality in Premenopausal Women with Idiopathic Fragility Fractures$128,386
K23 · FY2011 · AR · contact PI
Bone Quality in Premenopausal Women with Idiopathic Fragility Fractures$128,386
K23 · FY2010 · AR · contact PI
Bone Quality in Premenopausal Women with Idiopathic Fragility Fractures$128,386
K23 · FY2009 · AR · contact PI
Bone Quality in Premenopausal Women with Idiopathic Fragility Fractures$128,386
K23 · FY2008 · AR · contact PI
Bone Quality in Premenopausal Women with Idiopathic Fragility Fractures$128,386
K23 · FY2007 · AR · contact PI